By 2030, we aim to have global first-class drug discovery capabilities and be a top innovator in the healthcare industry, an innovator that patients around the world can count on. To achieve this, we will create shared value with society and deliver advanced and sustainable patient-centric healthcare.
-
Annual Report 2020 Main Report
Story of medium- to long-term value creation Download the entire report [PDF 13.5MB]
-
Annual Report 2020 Activities Report
Detailed short-term information Download the entire report [PDF 5.4MB]
Annual Report 2020 consists of two parts: a story of medium- to long-term value creation in the “Main Report” and detailed short-term information in the “Activities Report.”
Top Message
Top management talks about “Pursue innovation,” the keyword of Chugai’s value creation, its medium- to long-term growth strategy through 2030, and the creation of shared value with stakeholders.
Pursuit of Innovation Remains Key for Future Value Creation
The pursuit of innovation remains the key concept underpinning value creation at Chugai. We aim to support patients and society by genuinely addressing their hopes and expectations and delivering solutions to specific unmet medical needs.
Tatsuro Kosaka
Representative Director, Chairman
The goal is for all of our employees to work together toward the vision of making Chugai a top innovator in the healthcare industry by 2030.
By 2030, we aim to have global first-class drug discovery capabilities and be a top innovator in the healthcare industry, an innovator that patients around the world can count on. To achieve this, we will create shared value with society and deliver advanced and sustainable patient-centric healthcare.
Dr. Osamu Okuda
Representative Director,
President & CEO
We are evolving our efforts to create shared value.
We are evolving our efforts to create shared value by stepping up dialogue with stakeholders and factoring their hopes, expectations, and suggestions into the management of our business.
Motoo Ueno
Representative Director,
Deputy Chairman
In charge of Sustainability Dept., Audit Dept.
Value Creation by Chugai
In addition to introducing a value-creation model aimed at “creating shared value,” this report also provides in-depth explanations of the “Top Innovator in the Healthcare Industry” that we aim to achieve, in conjunction with interviews with executives from three perspectives: WHY, WHAT, and HOW. We also list the necessary capital investment and indicate the links to the enhancement of corporate value.
- Our History and Shared Value
- Value Creation Model
- Vision of Chugai as a Top Innovator in 2030 - Outlook for Chugai’s Business Environment in 2030
- Vision of Chugai as a Top Innovator in 2030 - Value Shared by a Top Innovator
- Vision of Chugai as a Top Innovator in 2030 - Key Drivers to Becoming a Top Innovator
- Capital Investment with a Focus on 2030
- Collaboration with Roche
See also the PDF below
Chugai has adopted “creating shared value” with stakeholders as its basic policy. We identified 25 material issues that should be given priority.
Targets and Progress in Material Issues [PDF 237KB]
Relationships of Indicators/
Financial and Pre-Financial Highlights/
Message from the CFO
Chugai has organized the relationship between financial indicators and key indicators that affect their financial performance (pre-financial indicators). In addition, this report contains contents to read and interpret Chugai from a number perspective, including financial and pre-financial highlights summarizing 10-year performance trends and major events, an overview of each disease area, and the status of development pipeline. Please read this together with the financial strategies described by the CFO.
- Relationships of Indicators
- Financial and Pre-Financial Highlights
- Review by Disease Area
- Development Pipeline
We are building the foundation for sustainable growth through further refinements in our unique cash generation cycle and a balanced allocation of capital.
Chugai will strengthen the cash generation cycle we have built based on our strategic alliance with Roche and increase our economic value. In addition, we will also pursue ESG initiatives and other programs to create shared value with society.
Toshiaki Itagaki
Executive Vice President & CFO
Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, Digital Strategy and IT Solution
Head of Finance Supervisory Div.
New Growth Strategy
“TOP I 2030”
The new growth strategy “TOP I 2030,” formulated in 2021, is based on the strategic alliance with Roche with the aim of acquiring further competitive advantages and realizing sustainable earnings growth and expanding corporate value. This section outlines our growth strategy and explains five reforms.
- Background to Growth Strategy Development
- New Growth Strategy TOP I 2030
- TOP I 2030 – 1. Drug Discovery
- TOP I 2030 – 2. Development
- TOP I 2030 – 3. Pharmaceutical Technology
- TOP I 2030 – 4. Value Delivery
- TOP I 2030 – 5. Foundation for Growth
[ Annual Report 2020 Contents ]
-
Main Report
Story of medium- to long-term value creation-
About Chugai / Messages
- Mission Statement
- Chugai’s Business Processes
- Themes over the Past Year
- Message from the Chairman
- Interview with the CEO
-
Value Creation by Chugai
- Value Creation by Chugai
- Our History and Shared Value
- Value Creation Model
- Vision of Chugai as a Top Innovator in 2030
- Capital Investment with a Focus on 2030
- Collaboration with Roche
-
Indicators and Performance
- Relationships of Indicators
- Financial and Pre-Financial Highlights
- Review by Disease Area
- Development Pipeline
-
Sustainability and Growth Strategies
- Sustainability and Growth Strategies
- Message from the Deputy Chairman
- Executive Officers
- Targets and Progress in Material Issues
- Main Risks and Countermeasures
- Background to Growth Strategy Development
- New Growth Strategy TOP I 2030
- Focus: CHUGAI DIGITAL VISION 2030／Mid-Term Environment Goals 2030
- Message from the CFO
-
Corporate Governance
- Enhancement of Corporate Governance
- Message from an Outside Director
- Directors / Audit & Supervisory Board Members
-
Corporate Data
- Shareholder Information
- Corporate Profile
-
-
Activities Report
Detailed short-term information-
Chugai in Action
- Chugai in Action
- Outline of Functions
- Response to the COVID-19 Pandemic
- Research
- Development
- Pharmaceutical Technology and Production
- Marketing
- Medical Affairs
- Drug Safety
- Quality and Regulatory Compliance
- Intellectual Property
- Human Resources
- Human Rights
- Environment, Health, and Safety (EHS)
- Social Contribution
- Global Health
-
Basic Information
- Basic Information
- Basic Information on the Pharmaceutical Industry
- Oncology
- Bone and Joint Diseases/Autoimmune Diseases
- Renal Diseases
- Neurology
- Other Diseases
-
Financial Information 55 Financial Information
- Financial Information 55 Financial Information
- Consolidated Financial Indicators
- Management’s Discussion and Analysis
- Business Risks
- Consolidated Financial Statements
-
